Aprea Therapeutics Inc (APRE) FinancialsAPREAprea Therapeutics Inc

Evaluating the bottom line, Aprea Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -61.84%, provide a clear picture of how effectively APRE converts its operational activities into shareholder value.

In the context of the broader market, APRE competes directly with industry leaders such as AIM and BGMS. With a market capitalization of $7.49M, it holds a leading position in the sector. When comparing efficiency, APRE's gross margin of N/A stands against AIM's 80.77% and BGMS's 23.51%. Such benchmarking helps identify whether Aprea Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Aprea has shown a significant decline in revenue, with total revenue dropping to $1,848 in Q3 2025 and net income consistently negative, reaching -$4,809,980 in Q3 2026. The gross margin has also dropped to 0% in recent quarters, indicating challenges in maintaining profitability.